Clinical bottom line
Novel systemic treatments, particularly Janus kinase (JAK) inhibitors, show emerging promise for managing generalized granuloma annulare (GA), a condition often refractory to conventional therapies. Recent systematic reviews highlight JAK inhibitors as effective options with acceptable safety profiles, though evidence remains limited by small sample sizes and short follow-up. Other systemic agents, including deucravacitinib, are under investigation but lack robust clinical data. Clinicians should consider JAK inhibitors for patients with widespread or treatment-resistant GA while weighing potential risks and monitoring requirements (Jaguan et al., 2026; D'Agostino et al., 2026).
What the evidence shows
Jaguan et al. (2026) conducted a systematic review of JAK inhibitors in generalized GA, reporting significant clinical improvement in most cases treated with agents such as tofacitinib and ruxolitinib. The review notes rapid lesion resolution and sustained responses in many patients, with adverse events generally mild and manageable.
D'Agostino et al. (2026) discuss deucravacitinib, a selective TYK2 inhibitor, highlighting its current dermatologic indications and potential off-label use in inflammatory skin diseases including GA. While promising mechanistically, clinical data specific to GA are sparse and primarily anecdotal.
Gyulai et al. (2023) provide a comprehensive overview of GA, emphasizing the challenges in treating generalized forms and summarizing systemic treatment options including corticosteroids, antimalarials, and immunomodulators, which often yield variable efficacy.
Woolhiser et al. (2024) systematically reviewed treatments for subcutaneous GA, underscoring the paucity of high-quality evidence and the need for controlled trials evaluating systemic therapies.
Caveats and uncertainty
Most evidence derives from case reports, small case series, or open-label studies lacking control groups.
Long-term safety and relapse rates following JAK inhibitor therapy in GA remain unclear.
Comparative efficacy versus established systemic agents has not been established.
Potential risks of immunosuppression and off-target effects require vigilant monitoring.
Data on newer agents like deucravacitinib are preliminary and require validation in controlled trials.
How this may change practice
For patients with generalized or refractory GA, JAK inhibitors may be considered as a therapeutic option after weighing benefits and risks.
Dermatologists should monitor for adverse effects, including infections and laboratory abnormalities, during treatment.
Emerging agents such as deucravacitinib warrant attention but should be used cautiously pending further evidence.
Multidisciplinary collaboration and patient education on novel therapies can optimize outcomes.
Future research should focus on randomized controlled trials to define optimal treatment algorithms.